DR HOLGER ZIMMERMANN JOINS LYSANDO ADVISORY BOARD

KUALA LUMPUR, Nov 8 (Bernama) -- Lysando, an innovator in the fight against antibiotic-resistant bacteria, has appointed Dr Holger Zimmermann to its Advisory Board.

Dr Zimmermann's distinguished career in the pharmaceutical sector and healthcare industry brings a wealth of experience, positioning him as a key asset in Lysando's mission to eliminate the fear of harmful bacteria worldwide.

Its Chairman of the Board of Directors, Count Markus Matuschka de Greiffenclau said Dr Zimmermann's profound experience in the pharmaceutical and healthcare sectors, coupled with a successful track record in product development, makes him a valuable addition to the team.

“His unique insights will play a pivotal role in guiding Lysando towards our ultimate goal of bringing life-enhancing solutions to market,” he said in a statement.

Meanwhile, Dr Zimmermann said: “I am excited to be able to support Lysando's mission to develop innovative products against disease-causing bacteria”.

Currently serving as the Chief Research and Development Officer at AiCuris AG, he has been instrumental in bringing innovative healthcare products to market and his extensive background in human pharmaceutical pre-clinical and clinical research underscores the transformative potential he brings to Lysando.

As a distinguished member of the Advisory Board, Dr Zimmermann will contribute invaluable knowledge and strategic guidance, particularly in navigating the challenges of the pharmaceutical industry.

Lysando has been a driving force in innovation against antibiotic-resistant bacteria, pioneering the revolutionary Artilysin technology that safeguards individuals from dangerous infections.

The company's dedication to curbing the dissemination of Antimicrobial Resistance aligns seamlessly with Dr. Zimmermann's expertise and vision.

-- BERNAMA